Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Kathleen J. Yost"'
Autor:
Lorenzo Cohen, Suzanne Danhauer, David Ira Rosenthal, Mark Steven Chambers, M. Kay Garcia, Andrew Cusimano, Mark Brown, Emily Van Meter Dressler, Jewel Ochoa, Peiying Yang, Joseph S Chiang, Ora Gordon, Rhonda Crutcher, Jung K Kim, Michael P. Russin, Joshua Lukenbill, Mercedes Porosnicu, Kathleen J Yost, Kathryn E. Weaver, Glenn Jay Lesser
Publikováno v:
Journal of Clinical Oncology. 40:12004-12004
12004 Background: The majority of head/neck (HN) patients who undergo radiotherapy develop RIX. Unfortunately, existing treatments are of limited benefit and have side effects. Initial small studies suggest acupuncture may treat chronic RIX. A multic
Autor:
Vijay S. Suhag, Forrest L. Thompson, Andrew L. Rygiel, Samiha Islam, Pam K. Mangat, Kathleen J. Yost, Alissa S. Marr, Ajjai Alva, Elizabeth Garrett-Mayer, Efrat Dotan, Olatunji B. Alese, Omid Hamid, Martin Clive Palmer, Eugene R Ahn, Eddy S. Yang, Carmen Julia Calfa, Susan Halabi, Sarah T. Anderson, Richard L. Schilsky
Publikováno v:
Journal of Clinical Oncology. 38:4637-4637
4637 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of pancreatic cancer pts with germline or somatic BR
Autor:
Rahma Warsame, Carrie A. Thompson, S. Vincent Rajkumar, Thomas E. Witzig, Thomas M. Habermann, Kathleen J. Yost, Gita Thanarajasingam, Morie A. Gertz, James R. Cerhan, Surbhi Sidana, Stephen M. Ansell, Cristine Allmer, Shaji Kumar, Wilson I. Gonsalves, Angela Dispenzieri, Amylou C. Dueck, Yi Lin, Melissa C. Larson, Jonas Paludo, Grzegorz S. Nowakowski
Publikováno v:
Journal of Clinical Oncology. 38:e19112-e19112
e19112 Background: We sought to study the longitudinal QOL, financial burden and perception of care (PoC) in patients with multiple myeloma (MM) or lymphoma (LYM) enrolled on CTs vs. those receiving standard care (Non-CT). Methods: QOL was evaluated
Autor:
Kelsey Klute, Venu Perla, Susan Halabi, Kathleen J. Yost, Elizabeth Garrett-Mayer, Nicole L. Butler, Reza Nazemzadeh, Richard L. Schilsky, Pam K. Mangat
Publikováno v:
Journal of Clinical Oncology. 38:122-122
122 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of CRC pts with BRAF V600E mutation treated with C+V
Autor:
Jose Villasboas Bisneto, Shaji Kumar, Gita Thanarajasingam, Kathleen J. Yost, Rahma Warsame, Mustaqeem A. Siddiqui, Yi Lin, Joan M. Griffin, N. Nora Bennani, Surbhi Sidana, Angela Dispenzieri, Patrick B. Johnston, Amylou C. Dueck, Andrea L. Cheville, Michelle Burtis, Carrie A. Thompson, Morie A. Gertz, Jonas Paludo, Stephen M. Ansell, S. Vincent Rajkumar
Publikováno v:
Journal of Clinical Oncology. 37:6594-6594
6594 Background: Given the significant short-term adverse effects of CAR-T cell therapy, it is important to evaluate its impact on QOL of patients in addition to efficacy, compared with established forms of cellular therapy like SCT. Methods: QOL was
Autor:
Asheesh Shipstone, Greg Yothers, Thomas J. George, Carmen J. Allegra, Kathleen J. Yost, James L. Wade, Peter C. Lucas, Samuel A. Jacobs, James J. Lee, Tatjana Kolevska, Katherine L. Pogue-Geile, Ashok Srinivasan, Philip J. Stella, Gary L. Buchschacher
Publikováno v:
Journal of Clinical Oncology. 37:TPS716-TPS716
TPS716 Background: HER2 has been shown to be a validated therapeutic target for the treatment of mCRC. Preclinical and clinical evidence supports the use of HER2-targeted agents in each of these mCRC cohorts. In HERACLES, treatment–refractory, KRAS
Autor:
Elizabeth Garrett-Mayer, Kathleen J. Yost, Richard L. Schilsky, Edward S. Kim, Kaitlyn R. Antonelli, Nicole L. Butler, Kuo Guo, Vaibhav Sahai, Susan Halabi, Andrew L. Rygiel, Eugene R Ahn, Suanna S. Bruinooge, Pam K. Mangat, Tareq Al Baghdadi, Ricardo H. Alvarez
Publikováno v:
Journal of Clinical Oncology. 36:2532-2532
2532Background: The TAPUR Study is a phase II multi‐basket study that evaluates the anti‐tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alteratio...
Autor:
Rahma Warsame, Daniela L. Stan, Joon H. Uhm, Carrie A. Thompson, Amanika Kumar, Alicia Bartz, Thomas E. Witzig, Paul J. Novotny, Kathleen J. Yost, Kathryn J. Ruddy, Jeff A. Sloan
Publikováno v:
Journal of Clinical Oncology. 36:6501-6501
6501Background: Patient-reported outcomes (PROs) are important measures in patients with cancer, but may be burdensome to collect. We aimed to measure PROs via mobile technology, using novel emoji ...
Autor:
Aaron D. Norman, Nwamaka Obidegwu, Leah Eshraghi, Elizabeth J. Cathcart-Rake, Kathleen J. Yost, Kathryn J. Ruddy, Celine M. Vachon, Fergus J. Couch, Kelly C. Gast
Publikováno v:
Journal of Clinical Oncology. 36:e22143-e22143
e22143Background: Patient-reports of chemotherapy treatments are often used in oncology research, including to assess predictors of recurrence and long-term side effects. The purpose of this study ...
Publikováno v:
Journal of Clinical Oncology. 36:174-174
174 Background: Patient-reported outcomes (PROs), including physical function and quality of life (QOL), are important outcomes in cancer patients. Emoji are a near-universal, popular form of communication, understandable by diverse populations, incl